ArticleDiscover oncology2025
Unraveling drug resistance mechanisms in testicular cancer through immune cell phenotypes: a bidirectional Mendelian randomization analysis revealing novel therapeutic targets.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWhile testicular cancer is highly curable, drug resistance remains a challenge in relapsed or refractory cases. This study explores the immune system's role in resistance mechanisms via bidirectional Mendelian Randomization (MR) analysis of 731 immune cell phenotypes.
methodWe conducted a two-sample bidirectional MR analysis using IVW, MR-Egger, weighted median, and other models, leveraging public genetic datasets. Sensitivity analyses were performed to ensure robustness and assess pleiotropy.
resultsThe MR analysis revealed 12 immune cell phenotypes causally linked to testicular cancer development and 16 phenotypes significantly modulated by the disease, highlighting potential therapeutic resistance mechanisms. Several identified immune markers were associated with known drug resistance pathways, suggesting novel therapeutic targets. Sensitivity analyses confirmed the robustness of our primary findings and their relevance to drug resistance mechanisms.
conclusionOur findings reveal immune-related mechanisms underlying drug resistance in testicular cancer, offering potential targets for overcoming therapeutic resistance and guiding future treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.